Holen Sie sich die Stockscreener-App
54.26
4.87%
2.52
Vorhandelsmarkt:
54.58
0.32
+0.59%
Schlusskurs vom Vortag:
$51.74
Offen:
$52.51
24-Stunden-Volumen:
2.41M
Relative Volume:
0.98
Marktkapitalisierung:
$10.04B
Einnahmen:
$2.69B
Nettoeinkommen (Verlust:
$-214.04M
KGV:
-46.38
EPS:
-1.17
Netto-Cashflow:
$98.43M
1W Leistung:
+0.11%
1M Leistung:
-8.65%
6M Leistung:
+15.92%
1J Leistung:
-17.60%
1-Tages-Spanne:
$52.37
$54.86
1-Wochen-Bereich:
$49.79
$56.48
52-Wochen-Spanne:
$40.62
$79.62
Exact Sciences Corp Stock (EXAS) Company Profile
Firmenname
Exact Sciences Corp
Sektor
Branche
Telefon
608-284-5700
Adresse
5505 ENDEAVOR LANE, MADISON, WI
Vergleichen Sie EXAS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EXAS
Exact Sciences Corp
|
54.26 | 10.04B | 2.69B | -214.04M | 98.43M | -1.17 |
|
TMO
Thermo Fisher Scientific Inc
|
573.06 | 219.20B | 42.37B | 6.14B | 7.78B | 15.95 |
|
DHR
Danaher Corp
|
244.11 | 176.31B | 23.74B | 3.89B | 4.98B | 5.24 |
|
A
Agilent Technologies Inc
|
152.57 | 43.57B | 6.51B | 1.29B | 1.37B | 4.42 |
|
IQV
Iqvia Holdings Inc
|
205.69 | 37.33B | 15.32B | 1.41B | 1.96B | 7.62 |
|
IDXX
Idexx Laboratories Inc
|
427.33 | 34.99B | 3.84B | 866.24M | 792.60M | 10.37 |
Exact Sciences Corp Stock (EXAS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-08-28 | Eingeleitet | Wells Fargo | Overweight |
| 2024-06-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-06-03 | Fortgesetzt | Jefferies | Buy |
| 2024-01-02 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2023-12-14 | Eingeleitet | Guggenheim | Buy |
| 2023-12-13 | Eingeleitet | Wolfe Research | Outperform |
| 2023-10-10 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-09-28 | Eingeleitet | Bernstein | Outperform |
| 2023-08-02 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2023-05-10 | Hochstufung | Craig Hallum | Hold → Buy |
| 2023-05-05 | Eingeleitet | UBS | Neutral |
| 2023-03-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-02-10 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2023-01-18 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2022-10-19 | Herabstufung | Craig Hallum | Buy → Hold |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-06-03 | Eingeleitet | Piper Sandler | Neutral |
| 2021-11-03 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2021-07-29 | Bestätigt | BTIG Research | Buy |
| 2021-07-29 | Bestätigt | Canaccord Genuity | Buy |
| 2021-07-29 | Bestätigt | Oppenheimer | Outperform |
| 2021-07-29 | Bestätigt | Stifel | Buy |
| 2021-06-15 | Eingeleitet | Raymond James | Strong Buy |
| 2021-06-03 | Eingeleitet | Goldman | Buy |
| 2021-05-25 | Eingeleitet | Wells Fargo | Equal Weight |
| 2021-01-28 | Eingeleitet | Truist | Buy |
| 2020-10-29 | Herabstufung | UBS | Buy → Neutral |
| 2020-10-28 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-10-08 | Fortgesetzt | BTIG Research | Buy |
| 2020-04-02 | Eingeleitet | Evercore ISI | Outperform |
| 2020-01-10 | Fortgesetzt | BTIG Research | Buy |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2019-12-13 | Eingeleitet | Dougherty & Company | Buy |
| 2019-11-15 | Eingeleitet | Stifel | Buy |
| 2019-10-17 | Bestätigt | BofA/Merrill | Buy |
| 2019-10-01 | Fortgesetzt | Craig Hallum | Buy |
| 2019-09-26 | Eingeleitet | Oppenheimer | Outperform |
| 2019-02-26 | Hochstufung | Goldman | Neutral → Buy |
| 2018-10-09 | Eingeleitet | UBS | Buy |
| 2018-09-05 | Fortgesetzt | The Benchmark Company | Hold |
| 2018-08-13 | Bestätigt | Canaccord Genuity | Buy |
| 2018-04-03 | Hochstufung | BTIG Research | Neutral → Buy |
| 2018-01-29 | Eingeleitet | Goldman | Neutral |
| 2018-01-08 | Bestätigt | The Benchmark Company | Buy |
| 2017-11-13 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2017-11-01 | Herabstufung | BTIG Research | Buy → Neutral |
Alle ansehen
Exact Sciences Corp Aktie (EXAS) Neueste Nachrichten
Exact Sciences to launch Oncodetect MRD test in Q2 2025 - Investing.com India
Exact Sciences (EXAS): New Evidence Validates Oncodetect's Ability to Detect Molecular Residual Disease and Predict Recurrence in Colorectal Cancer Patients - StreetInsider.com
Exact Sciences' Oncodetect MRD Test Shows Breakthrough 91% Cancer Detection Rate in Clinical Trial - StockTitan
Exact Sciences (NASDAQ:EXAS) Trading Up 5%Time to Buy? - MarketBeat
Avanza Fonder AB Acquires Shares of 19,512 Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat
5,782 Shares in Exact Sciences Co. (NASDAQ:EXAS) Acquired by Retirement Wealth Solutions LLC - MarketBeat
Exact Sciences (NASDAQ:EXAS) Stock Price Down 4.3%What's Next? - MarketBeat
Why Exact Sciences (EXAS) Is Crashing? - Insider Monkey
Exact Sciences Stock Drops 12% Over Four Days. 'What Is Going On?' - Yahoo! Voices
Beech Hill Advisors Inc. Sells 11,383 Shares of Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat
2 Healthcare Stocks to Buy Hand Over Fist in January - Yahoo Finance
Exact Sciences (NASDAQ:EXAS) Shares Gap UpStill a Buy? - MarketBeat
Exact Sciences (NASDAQ:EXAS) Trading Down 4.3%Here's Why - MarketBeat
William Blair Reaffirms "Outperform" Rating for Exact Sciences (NASDAQ:EXAS) - MarketBeat
Exact Sciences Stock Surges with Strong Financials - TipRanks
Exact Sciences Sparks Analyst Optimism Amid Competitive Multi-Cancer Test Market - Benzinga
Exact Sciences (NASDAQ:EXAS) Given Buy Rating at Benchmark - MarketBeat
Exact Sciences Boosts Finances and Plans New Launches - TipRanks
Exact Sciences expects Q4 and FY revenue to beat estimates - MSN
Exact Sciences Reports 10% Revenue Jump to $713M, Plans Three New Cancer Tests for 2025 - StockTitan
Exact Sciences Announces Preliminary Fourth Quarter 2024 Results - Yahoo Finance
Exact Sciences Co. (NASDAQ:EXAS) Shares Acquired by Harbor Capital Advisors Inc. - MarketBeat
Q2 EPS Estimate for Exact Sciences Increased by Analyst - MarketBeat
Should Exact Sciences Stock Stay in Your Portfolio Right Now? - Yahoo Finance
Exact Sciences Co. (NASDAQ:EXAS) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
Exact Sciences Corporation Announces Appointment of Kim Popovits as A Class I Member of the Board - Marketscreener.com
Exact Sciences to participate in J.P. Morgan Healthcare Conferen - GuruFocus.com
Exact Sciences price target raised to $70 from $60 at Evercore ISI - Yahoo Finance
Exact Sciences to Participate in J.P. Morgan Healthcare Conference - Marketscreener.com
Exact Sciences to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
Exact Sciences Announces Second-Quarter 2023 Results - GuruFocus.com
Exact Sciences Co. (NASDAQ:EXAS) Short Interest Down 5.3% in December - MarketBeat
Exact Sciences and Lil Jon Partner on Get Low #2 Campaign to Encourage Colon Cancer Screening - La Opinión
(EXAS)Analyzing Exact Sciences's Short Interest - Benzinga
Exact Sciences Corporation's (NASDAQ:EXAS) Shift From Loss To Profit - Simply Wall St
Principal Financial Group Inc. Has $71.48 Million Stock Position in Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat
Tidal Investments LLC Grows Holdings in Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat
Exact Sciences Co. (NASDAQ:EXAS) Shares Sold by Toronto Dominion Bank - MarketBeat
Exact Sciences Co. (NASDAQ:EXAS) Shares Sold by Public Employees Retirement System of Ohio - MarketBeat
Exact Sciences (NASDAQ:EXAS) Price Target Lowered to $72.00 at Bank of America - MarketBeat
Exact Sciences Co. (NASDAQ:EXAS) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Exact Sciences: Profitability Remains Elusive (NASDAQ:EXAS) - Seeking Alpha
Groupama Asset Managment Acquires Shares of 1,204,952 Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat
Exact Sciences Corp reports results for the quarter ended in September 30Earnings Summary - XM
AAPA Awarded Grant from Exact Sciences to Improve Colorectal Cancer Screening Rates - Yahoo Finance
Pier Capital LLC Takes Position in Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat
Soros Fund Management LLC Boosts Holdings in Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat
Lil Jon Remixes Iconic ‘Get Low’ Hit To Promote Colon Cancer Screenings - Black Enterprise
Polar Asset Management Partners Inc. Acquires 45,800 Shares of Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat
Exact Sciences Co. (NASDAQ:EXAS) Shares Bought by Cerity Partners LLC - MarketBeat
Exact Sciences Corp (EXAS) Shares Up 4.18% on Dec 4 - GuruFocus.com
Finanzdaten der Exact Sciences Corp-Aktie (EXAS)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.28%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):